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Capillary-based PCR ribotyping was used to quantify the presence/absence and relative abundance of 98 Clostridium difficile
ribotypes from clinical cases of disease at health care institutions in six states of the United States. Regionally important
ribotypes were identified, and institutions in close proximity did not necessarily share more ribotype diversity than institutions
that were farther apart.
National and international studies strongly suggest that Clos-tridiumdifficile populations are geographically distinct (1–5),
meaning the composition of C. difficile genotypes varies from re-
gion to region. In the United States, there are currently few data
concerning the composition, or structure, of the C. difficile popu-
lation and whether health care institutions that are in close prox-
imity are more similar with respect to ribotype diversity than
those that are farther apart. The goals of this study were to quantify
the abundance and diversity of C. difficile ribotypes from cases of
C. difficile infection (CDI) at health care institutions in six states
across the United States and to determine whether ribotype diver-
sity was structured geographically.
Stool samples from CDI-positive patients were collected from
diagnostic laboratories at six health care institutions (West Rox-
bury, MA; York, PA; Ann Arbor, MI; St. Louis, MO; Portland, OR;
and North Hollywood, CA) between 15 February 2011 and 9 Sep-
tember 2011 and shipped in small batches (typically 5 to 10 sam-
ples) overnight on ice to the University of Michigan for processing
(Ann Arbor, MI, samples were obtained directly from the Clinical
Microbiology Laboratory at the University of Michigan Health
System and were not shipped). A variety of CDI diagnostic meth-
ods were represented across the institutions (Table 1), and CDI
cases were defined based on center-specific diagnostic results. In-
stitutional review board (IRB) approval was obtained as appropri-
ate by the participating institutions. Culture was attempted for all
samples submitted by each center. On three occasions, samples
from three centers were unable to be processed (i.e., plated) within
24 h of receiving due to the lack of available study personnel. These
samples were not included in the study. An aliquot from each
sample was cultured under anaerobic conditions on prereduced
taurocholate cefoxitin cycloserine fructose agar (TCCFA) plates
to select for individual C. difficile colonies (6). All TCCFA plates
were prepared at the University of Michigan. All samples were
frozen at80°C and recultured a second time if the first attempt
at culture was unsuccessful. A single colony was analyzed from
each stool sample, and the toxigenicity of isolates was inferred
based on results of PCR for a C. difficile-specific region of the 16S
rRNA-encoding gene (7) and tcdA (toxin A) or tcdB (toxin B) (8).
The absence of tcdA or tcdB was not confirmed for all isolates (i.e.,
tcdA can be variably present/absent and primers may or may not
amplify all tcdA/tcdB alleles), but all toxigenic isolates were posi-
tive for at least one toxin gene. Potential nontoxigenic isolates
identified as toxin gene negative by PCR were confirmed as C.
difficile using specific 16S gene PCR and confirmed as nontoxi-
genic using a Vero cell assay (9). A range of isolates from each
center (79% to 94%) were confirmed to be toxigenic C. difficile
(Table 1), and the overall recovery of toxigenic isolates did not
differ significantly across the six centers (P 0.074). Although not
significantly different, samples that tested positive by enzyme im-
munoassay (EIA) alone (Missouri) tended to have a higher cul-
ture-positive rate than the other centers that used nucleic acid
amplification testing (NAAT) (Table 1). Whether EIA positivity is
more predictive of C. difficile growth on TCCFA than NAAT pos-
itivity remains an interesting question to be addressed in further
studies.
Fluorescent PCR ribotyping was conducted using capillary gel
electrophoresis as previously reported (10), and a total of 98 dif-
ferent ribotypes were identified. Approximately half (n  50) of
the ribotypes were observed at least twice, and the remaining half
(n  48) were observed a single time (i.e., a single isolate). The
number of toxigenic ribotypes at a particular site correlated sig-
nificantly with the number of isolates examined (Pearson correla-
tion; P  0.006; R2  0.87), indicating that additional ribotypes
would have been identified with deeper sampling. We had initially
hoped that our sampling design would provide an overall estimate
of the number of toxigenicC. difficile ribotypes in U.S. circulation.
However, the strong (R2 0.87), near-linear relationship between
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the number of ribotypes observed and the number of isolates
examined indicated that we identified only the most abundant
ribotypes at each institution and that the actual number of toxi-
genic C. difficile ribotypes is much greater than 98. Other collec-
tions have identified, or at least named, over 270 different ri-
botypes (11). However, there are few data with which to compare
the total number of ribotypes within or between countries because
there is currently no internationally recognized C. difficile ri-
botype reference collection. For example, a collection of 80 C.
difficile ribotypes was recently published (11), but it is not clear
whether non-European representative isolates were included in
this collection. In this study, we identified 10 ribotypes for which
we had reference cultures. The identity of the remaining 88 ri-
botypes and international data comparison rely on the future es-
tablishment of a representative C. difficile ribotype collection.
A median of 7.6% (range, 0.0% to 11.0%) of isolates per insti-
tution were specific to a single location, indicating that a signifi-
cant percentage of CDI-causing isolates were regionally versus
nationally important. Contingency table analysis with a Bonfer-
roni correction (P value/total number of tests) indicated that the
abundance of ribotype 027 was statistically different (P 0.0005)
across the six institutions (Table 2). Ribotype 027 was more abun-
dant than any other ribotype at four out of six sites, but 014-020
was the most abundant at the Oregon site and nearly equal to 027
at the Michigan site. To visualize how similar institutions were
with respect to the overall composition of C. difficile ribotypes, we
used an ecological diversity metric (Morisita-Horn) to cluster
sites based on similarity (Fig. 1). This type of analysis considers
both the presence/absence and the relative abundance of all
ribotypes (not just a select few). Branch lengths in the resulting
dendrogram are then proportional to C. difficile population sim-
ilarity (i.e., the more similar that sites are in ribotype composition,
the shorter the branches connecting them). Therefore, if the dis-
tance between institutions has a strong influence on ribotype di-
versity, we would expect institutions in close proximity to cluster
together in the dendrogram. Two main clusters (A and B) were
observed, but they were not easily explained by geographic prox-
imity (e.g., Oregon is closer to California than Michigan). Alter-
natively, abundance data (Table 2) indicated that the two clusters
differed noticeably in ribotype 027 and 014-020 abundance. For
example, a median of 32% of isolates (range, 25% to 51%) were
ribotype 027 at sites in Pennsylvania, Missouri, California, and
Massachusetts (cluster A), as opposed to only 11% in Oregon and
19% in Michigan (cluster B).
At this level of sampling, it appears that U.S. health care insti-
tutions can be differentiated by the high versus moderate abun-
dance of ribotype 027. Data from Wilcox et al. found that 027
abundance decreased significantly in England from 2007 to 2010
(5) but remained the most abundant ribotype in the country
(overall,30%). The Wilcox et al. study included 11,294 isolates,
compared to 720 isolates in our study, so there is a large discrep-
ancy between the two with respect to overall sample size. How-
ever, it is not directly apparent from the Wilcox et al. paper how
many isolates were included from each institution and over what
period of time, so a direct per-center comparison of sample size is
difficult to assess. Temporal data are needed to determine whether
U.S. trends mirror those of England and other countries, but our
results confirm that ribotype 027 is currently as abundant as or
even less abundant than other toxigenic ribotypes at some U.S.
institutions.
A tracking study of C. difficile disease at health care institutions
in selected counties of 10 U.S. states was initiated in 2009 by the
Centers for Disease Control and Prevention (http://www.cdc.gov
/hai/eip/clostridium-difficile.html). Results from this study pre-
sented at the Society for Healthcare Epidemiology of America
TABLE 1 Stool samples and C. difficile isolates obtained from confirmed CDI cases at six health care institutions in the United States
Institution









MA GeneXpert 125 103 (82) 0 (0) 103 (82)
PA GeneOhm 120 106 (88) 3 (3) 103 (86)
MI GDH/TOX EIA
GeneOhm 289 261 (90) 8 (3) 253 (88)
MO C. difficile TOX
A/B II 48 45 (94) 0 (0) 45 (94)
OR GDH/TOX EIA
GeneXpert 120 98 (82) 3 (3) 95 (79)
CA GeneXpert 150 121 (81) 0 (0) 121 (81)
Total 852 734 (86) 14 (2) 720 (85)
a CDI diagnostic test performed at each institution prior to shipping of samples: GeneXpert (Cephied, Sunnyvale, CA), GeneOhm (Becton, Dickinson, and Company, Franklin
Lakes, NJ), GDH/TOX EIA (C. Diff Quik Chek Complete; TechLab, Blacksburg, VA), and C. difficile TOX (C. difficile TOX A/B II; TechLab, Blacksburg, VA).
TABLE 2 Ribotype abundance at six U.S. health care institutions
Ribotype






CI)aPA MO CA OR MA MI
027 43 (42) 23 (51) 29 (24) 10 (11) 28 (27) 48 (19) 181 (29, 13–45)
014-020 15 (15) 6 (13) 5 (4) 14 (15) 7 (7) 39 (15) 86 (12, 7–17)
UM11 7 (7) 2 (4) 11 (9) 4 (4) 4 (4) 8 (3) 36 (5, 3–8)
053-163 4 (4) 1 (2) 4 (3) 6 (6) 8 (8) 13 (5) 36 (5, 2–7)
002 2 (2) 2 (4) 9 (7) 5 (5) 6 (6) 9 (4) 33 (5, 3–7)
001 1 (1) 1 (2) 7 (6) 3 (3) 2 (2) 12 (5) 26 (3, 1–5)
078-126 1 (1) 1 (2) 2 (2) 4 (4) 3 (3) 11 (4) 22 (3, 1–4)
017 1 (1) 1 (2) 4 (3) 3 (3) 1 (1) 10 (4) 20 (2, 1–4)
UM67-69 5 (5) 2 (4) 1 (1) 1 (1) 5 (5) 4 (2) 18 (3, 1–5)
UM5 4 (4) 1 (2) 2 (2) 3 (3) 1 (1) 7 (3) 18 (3, 1–4)
UM33-35 5 (5) 0 (0) 0 (0) 2 (2) 3 (3) 7 (3) 17 (2, 0–4)
UM8 3 (3) 0 (0) 2 (2) 2 (2) 1 (1) 9 (4) 17 (2, 1–4)
UM9 0 (0) 0 (0) 1 (1) 4 (4) 0 (0) 6 (2) 11 (1, 0–3)
UM16 3 (3) 0 (0) 1 (1) 1 (1) 0 (0) 5 (2) 10 (1, 0–2)
UM24 0 (0) 0 (0) 2 (2) 2 (2) 2 (2) 4 (2) 10 (1, 0–2)
Other 9 (9) 5 (11) 41 (34) 31 (33) 32 (31) 61 (24) 179 (24, 12–35)
Total 103 (14) 45 (6) 121 (17) 95 (13) 103 (14) 253 (35) 720
a CI, confidence interval.
Multi-Institution C. difﬁcile Ribotype Diversity
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(SHEA) conference in 2011 indicated that ribotype 027 isolates
(also known as North American pulsed-field gel electrophoresis
type NAP1) comprised 28% of the C. difficile population (322
isolates from hospitalized patients across five centers in 2010)
(12). Our finding of a mean 027 abundance of 29% across six
centers supports this general finding. An important detail that our
data show, however, is that 027 abundance varies widely across
institutions (13% to 45%).
In light of recent data from Tenover et al. (13), heterogeneity in
C. difficile ribotype composition may potentially influence CDI
diagnostic results. Recently published guidelines recommend ei-
ther the sole use of high-sensitivity nucleic acid amplification test-
ing (NAAT) or a two- or three-step algorithm composed of EIA
(for glutamate dehydrogenase [GDH] and/or C. difficile toxin)
and NAAT (14). Since EIA is currently cheaper than NAAT, EIA
may remain useful as a prescreening tool in clinical laboratories.
Thus, additional studies should be conducted to estimate the ef-
fect of ribotype diversity on false-positive/false-negative rates
across institutions.
A limitation of our study design was the use of deidentified
patient samples. We therefore were unable to account for dupli-
cate samples or recurrent and nonnosocomial cases. Another im-
portant limitation was that only one C. difficile colony per sample
was considered. It is possible that cultivable, toxigenic isolates
would have been recovered from samples that yielded nontoxi-
genic isolates, although the overall number of nontoxigenic iso-
lates was low and not likely to have significantly influenced our
overall results. It is also possible that more than one toxigenic C.
difficile ribotype was present in the same sample. Such cases are
not necessarily rare and may comprise up to 13% of samples in
some situations (15). Future studies that incorporate deeper sam-
pling are needed to understand the rate of mixed CDI among
health care institutions.
In summary, C. difficile ribotype data from six health care in-
stitutions across the United States suggest that there are many
(98) different ribotypes in circulation and that there is signifi-
cant heterogeneity in ribotype composition across these regions.
The abundance of ribotypes 027 and 014-020, but not geographic
proximity, correlated with compositional variation between C.
difficile populations. Finally, our results illustrate the potential
importance of regionally versus nationally circulating isolates
(7.6%) as well as the presence of a large amount of under-
sampled C. difficile genetic diversity. More-representative data of
C. difficile populations, including these rarer members, are needed
to better assess the impact of ribotype on sensitivity/specificity of
currently used diagnostic algorithms and clinical treatment of
CDI.
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